Title: Clinical Manifestations and Outcome of Viral Acute Lower Respiratory Infection in Hospitalised Children in Myanmar

Kazuhiro Kamata  
Infectious Disease Research Center of Niigata University

Khin Nyo Thein  
Yankin Children Hospital

Lasham Di Ja  
Infectious Disease Research Center of Niigata University

Nay Chi Win  
Infectious Disease Research Center of Niigata University

Su Mon Kyaw Win  
Infectious Disease Research Center of Niigata University

Yuko Suzuki  
Niigata University Graduate School of Medical and Dental Sciences

Ai Ito  
Niigata University Graduate School of Medical and Dental Sciences

Hidekazu Osada  
Niigata University Graduate School of Medical and Dental Sciences

Irina Chon  
Niigata University Graduate School of Medical and Dental Sciences

Wint Wint Phyu  
Niigata University Graduate School of Medical and Dental Sciences

Yuta Aizawa  
Niigata University Graduate School of Medical and Dental Sciences

Tatsuki Ikuse  
Niigata University Graduate School of Medical and Dental Sciences

Tomomi Ota  
Infectious Disease Research Center of Niigata University

Yadanar Kyaw  
Thingangyun Sanpya General Hospital

Htay Htay Tin  
National Health Laboratory

Yugo Shobugawa  
Niigata University Graduate School of Medical and Dental Sciences

Hisami Watanabe  
Niigata University Graduate School of Medical and Dental Sciences

Reiko Saito  
Niigata University Graduate School of Medical and Dental Sciences

Akihiko Sai (asaitoh@med.niigata-u.ac.jp)  
Niigata University Graduate School of Medical and Dental Sciences

---

Research Article

Keywords: acute lower respiratory infection, virus, children, respiratory syncytial virus, influenza, Myanmar

DOI: https://doi.org/10.21203/rs.3.rs-604402/v1

License: ©  This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Acute lower respiratory infection (ALRI) remains the leading cause of death in children worldwide, and viruses have been the major causative factors of ALRI after the introduction of bacterial conjugate vaccines. In Myanmar, ALRI is associated with high morbidity and mortality in children. However, detailed information on ALRI is currently lacking.

Methods

We conducted a prospective study to investigate the viral aetiologies, clinical manifestations, and outcomes of ALRI in hospitalised children at the Yankin Children Hospital, Yangon, Myanmar from May 2017 to April 2019. The World Health Organization’s definitions of ALRI and severe ALRI were used with minor modifications. For the patients with suspected viral ALRI, a nasopharyngeal swab was obtained, and rapid tests for influenza and respiratory syncytial virus (RSV) were performed, followed by real-time PCR for the 16 respiratory viruses causing ALRI. Clinical information was extracted from the medical records.

Results

Among the 5463 patients admitted with a diagnosis of ALRI, 570 (10.4%) were randomly enrolled in the study. The median age of the patients was 8 months (interquartile range, 4–15 months). The most common symptoms were cough (93%) and difficulty of breathing (73%), while the most common signs were tachypnoea (78%) and chest indrawing (67%). Sixteen potentially causative viruses were detected in 502 (88%) patients, with RSV B (36%) and rhinovirus (28%) being the most commonly detected. Multiple viruses were detected simultaneously in 221 patients (37%). Severe ALRI was diagnosed in 107 patients (19%). The mortality rate was 5%; influenza virus A (29%) and RSV B (21%) were commonly detected in such cases.

Conclusions

Viral ALRI in children has significant morbidity and mortality rates in Myanmar. RSV and rhinovirus were the most commonly detected, while influenza virus and RSV were the most common causes of mortality.

Background

Acute lower respiratory infection (ALRI), which comprises bronchitis, bronchiolitis, and pneumonia, remains the leading cause of death worldwide, accounting for 10% of deaths in children younger than 5 years (1-3). Remarkable progress in ALRI prevention and treatment has been achieved in the last few decades in developing countries. Key factors include the improvement of nutrition and sanitation, distribution and use of antibiotics and antivirals for influenza, and global promotion of the use of Haemophilus influenzae type b (Hib) vaccine and pneumococcal conjugate vaccines (PCV) in infants and children. In fact, between 2000 and 2015, the incidence of pneumonia among children younger than 5 years decreased by 30% (178 million in 2000 to 138 million in 2015), and the number of deaths in young children was almost halved (1.7 million in 2000 to 0.9 million in 2015) (4, 5). However, ALRI has been associated with the highest mortality in children compared to that of other infectious diseases, such as diarrhoea and malaria, with more than 95% of deaths occurring in low- and middle-income countries (6-8). Thus, continuous efforts and future strategies are needed to overcome the high mortality caused by ALRI in children.

ALRI in children is caused by various pathogens, including bacteria (e.g. Streptococcus pneumoniae, Haemophilus influenzae) and viruses (e.g. respiratory syncytial virus [RSV], influenza virus, etc.) (5). However, recent studies in the United States have demonstrated that most pneumonia cases in children were caused by a small set of viral pathogens, not bacteria (9-11). This shift has also been observed in some developing countries in Asia and Africa, including Bangladesh, India, Kenya, and Zambia (9, 11, 12), as viral pathogens, including RSV, human rhinovirus (hRV), human metapneumovirus (hMPV), human bocavirus (hBoV), parainfluenza viruses (PIV), and influenza virus, have been frequently identified in children with ALRI (12-14). It is assumed that the improvement and widespread availability of molecular diagnostics and the extensive immunisation programs for Hib and PCV have accelerated this trend, increasing the relative importance of viral aetiologies in children with ALRI (15). Notably, viral diagnosis has become extremely important during the global pandemic caused by the coronavirus disease in 2020 (16).

Myanmar is a lower-middle-income country in Asia that has been developing and expanding significantly after the political reform and democratisation in 2011. The Hib vaccine and 10-valent PCV were introduced in 2012 and 2016, respectively (17). Both are recommended at ages 2, 4, and 6 months without a booster dose after the first year (18). The immunisation coverage rates in 2017 were estimated to be approximately 90% for the third dose of both vaccines (19). Nevertheless, the serious issue of the high childhood mortality rate is still present in Myanmar as the under-five mortality rate in 2016 was 51 per 1,000 live births, the majority of which were attributable to ALRI, diarrhoea, or septicaemia (20, 21).
However, little has been reported on ALRI in children in Myanmar. Based on the data collected from the refugees living on the Thailand-Myanmar border (22), the influenza virus has a strong link to neighbouring countries (23), and RSV and influenza virus were frequently detected in children less than 5 years and equal or greater than 5 years, respectively (22).

To better understand the viral aetiologies, clinical manifestations, and clinical outcomes of ALRI in children in Myanmar, we performed a prospective study in one of the largest children's hospitals in Yangon, Myanmar. The results obtained in this study will lead to better strategies in preventing and/or treating viral ALRI and decreasing its associated morbidity and mortality in Myanmar.

Methods

Study design and study population

This prospective study investigated the clinical characteristics, clinical outcomes, and viral aetiologies in children in Myanmar who were admitted to the Yankin Children Hospital (YKCH) in Yangon, Myanmar for ALRI from April 2017 to March 2019. YKCH, affiliated with the University of Yangon, Medicine II, is one of the largest children's hospitals in Yangon with 550 beds. It plays a central role from the primary to tertiary care of children in the Yangon metropolitan area, which has a childhood population of more than 1.7 million (24). We randomly enrolled patients aged 1 month to 12 years who were admitted to the general wards or the intensive care unit at YKCH under the diagnosis of ALRI. The maximum age at admission at YKCH was 12 years.

Based on the World Health Organization (WHO) definition (25, 26), ALRI was defined as 1) history or measured fever of \( \geq 38^\circ C \), 2) cough, 3) onset within the last 10 days, and 4) hospitalisation requirement. Particularly for patients aged \(< 5 \) years, ALRI was defined as 1) fast breathing: less than 2 months: \( \geq 60 \) bpm, 2 months to less than 12 months: \( \geq 50 \) bpm, 12 months to less than 5 years: \( \geq 40 \) bpm, or 2) difficulty of breathing with chest indrawing and cough.

As for the patient characteristics, stunting was categorised using the height-for-age z-score: normal, \( \geq -2 \); moderate, \( \geq -3 \) to \( < -2 \); severe, \( < -3 \) (21). Tachycardia was defined as a heart rate \( \geq 160 \) bpm in children aged \(< 1 \) year and \( \geq 120 \) bpm in children aged \( \geq 1 \) year (14). Hypoxemia was defined as peripheral oxygen saturation \( (SpO_2) \leq 90\% \) by pulse oximetry (14, 26). Tachypnea was defined as a respiratory rate of \( \geq 60 \) bpm in children aged \(< 2 \) months, \( \geq 50 \) bpm in children aged 2–11 months, and \( \geq 40 \) bpm in children aged \( \geq 1 \) year (14, 25, 26). Fever was defined as a body temperature \( \geq 38.0^\circ C \) (14).

The laboratory examinations, including blood tests, bacterial culture, and chest radiographs, were ordered according to the physicians' discretion. Radiological findings were evaluated by senior paediatricians using an endpoint of consolidation, over-inflation, and whether or not the findings were unilateral or bilateral. Admission criteria were based on each physician's decision. However, the majority of the reasons for admission were 1) requirement of supplemental oxygen due to hypoxia, 2) requirement of hydration due to intolerable oral feeding, and/or 3) poor general condition.

Exclusion criteria for this study included those who 1) were recently hospitalised with acute respiratory illness within 7 days, 2) had already been enrolled in this study \(< 28 \) days, 3) diagnosed with bacterial ALRI by physical examination and microbiological tests (blood, nasopharyngeal and oropharyngeal swab, or sputum cultures); 4) had an alternative diagnosis of other respiratory disorders; 5) had a tracheostomy tube; or 6) had baseline diseases causing immunocompromised or altered respiratory status, such as chromosomal abnormalities, cancer, known respiratory diseases (bronchiectasis, cystic fibrosis, etc.), cerebral palsy, and human immunodeficiency virus infection.

All patients were conclusively diagnosed with ALRI by senior paediatricians. They also interviewed enrolled children and their caregivers using standardised questionnaires to collect information regarding the baseline characteristics and medical history. Data from medical records were abstracted systematically after discharge.

Definition of severe ALRI

Severe ALRI was defined when children with ALRI had 1) central cyanosis or \( SpO_2 \leq 90\% \), 2) severe respiratory distress, or 3) “general danger signs,” such as inability to drink, persistent vomiting, convulsions, or unconsciousness (25, 26). The WHO definition was designed for children aged 2 months to 5 years, but we adapted the definition to 1 month to 12 years to simplify the study criteria at the study site.

Nasopharyngeal sampling and microbiological analyses

At the time of admission, paediatricians collected nasopharyngeal samples from the patients who satisfied the case definition and agreed to participate in the study. The samples were stored at -80°C in a freezer at YKCH and were subsequently transported to the laboratory of Niigata University, Japan.
After thawing, the samples were centrifuged at 1500 × g for 30 min at 4°C, and the supernatants were used in the analysis. Viral RNA and DNA were extracted using a QIAamp MinElute Virus Spin Kit (QIAGEN, Valencia, CA, USA). Real-time reverse transcription PCR (RT-PCR) was performed using the One Step PrimeScript RT-PCR Kit (TaKaRa, Tokyo, Japan) with virus-specific primers and a TaqMan probe. For the RNA virus, the thermocycling settings were as follows: 42°C for 5 min for cDNA synthesis, 95°C for 3 min followed by 45 cycles at 95°C for 5 s for denaturation, and 60°C for 40 s for annealing and extension, except for human coronavirus (hCoV), which was under different conditions (46°C for 40 s for the annealing and extension process). Regarding the DNA virus, the thermocycling settings were as follows: 95°C for 3 min followed by 45 cycles at 95°C for 5 s for denaturation, and 60°C for 40 s for annealing and extension. Using this PCR assay with recorded CT values to estimate RNA or DNA levels, 16 viruses were examined: RSV (RSV A and RSV B), hRV, influenza virus (influenza A and influenza B), hMPV, enteroviruses, PIV (PIV 1-3), human coronavirus (hCoV; NL63, OC43, 229E, and HKU), adenovirus, and hBoV (27-36) (Supplementary Table 1).

In addition to the 16 viruses, a real-time PCR assay for *Streptococcus pneumoniae* (37-39) was performed to estimate colonisation rates. Real-time PCR was performed using the specific primers designed to target the following genes: cps-A and Takara SYBR Premix Ex Taq II (Product code: RR820A; TaKaRa, Tokyo, Japan). The thermocycling conditions were as follows: 95°C for 30 s, followed by 40 cycles at 95°C for 5 s for denaturation, and 60°C for 30 s for annealing and extension.

**Study outcomes**

The primary outcome of this study was to clinically characterise the ALRI patients with in-hospital mortality. The secondary outcome was the identification of viral pathogens that caused ALRI.

**Sample size calculation**

Based on the YKCH statistics from 2015-2016, the annual inpatient admission of ALRI was reported to be approximately 3,000 cases. Due to the limited study funding and manpower, the sample size was set to 300 patients each year, and we tried to recruit the patients each month to observe the pathogens causing ALRI at different time points in 2 years.

**Statistical analyses**

Paper-based survey data were entered independently and in duplicate by the study team. Data are reported as the median and interquartile range (IQR) or as the mean and standard deviation (SD) or percentages, where appropriate. Categorical variables were analysed using the χ² test, and continuous variables were assessed using the Mann-Whitney U test. Statistical significance was set at p < 0.05. Statistical testing was performed using the Statistical Package for the Social Sciences (ver. 24) (IBM, Armonk, NY, USA).

**Ethical approval**

All methods used in the current study were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all the study participants, including their parents and guardians, before they participated in the study. This study was approved by the ethics committees of the Department of Medical Research, Ministry of Health and Sports, Myanmar (016616) and Niigata University, Japan (2547).

**Results**

**Baseline characteristics of the ALRI patients (Table 1)**

In total, 5,463 children diagnosed with ALRI were admitted to the YKCH between 1 April 2017 and 30 March 2019. The average number of admissions was 228 patients/month, and the number of patients admitted in 2017 and 2018 were 2,467 and 2,996, respectively. The number of ALRI cases peaked during the rainy season in both years, with the highest peak observed in September (solid line, Figure 1). Of these, 570 (10.4%) eligible children were enrolled in the study. The clinical characteristics of the patients classified by age, severity, and detected number of viruses are summarised in Table 1 and Supplementary Table 2. The median age of the patients was 8 months (IQR: 4–15 months), and 56.5% were male. Moderate to severe stunting (weight for age Z score <-2) was observed in 138 (25%) patients. Among the eligible patients, 49.6% (n = 262) and 70.5% (n = 372) had received the 10-valent PCV10 and Hib vaccines (n = 528), respectively. Sick contact was observed in only 11% (65/570) of the patients. As for the time from the onset of disease, 70% (401/507) visited the hospital and received health care equal to or greater than 3 days after the onset of symptoms. The most common symptoms were cough (94%) and difficulty of breathing (73%).

**Physical examination and clinical course (Table 2 and Supplementary Table 3)**

Among the vital signs, tachypnoea was the most common finding (78%), with a median of 60 bpm (IQR: 48-64 bpm), followed by fever (≥38.0°C) (41%), and tachycardia (36%) (Table 2). On physical examination, chest indrawing, rhonchi, and coarse crackles were commonly observed in 67%, 63%, and 51% of the patients, respectively. Patients with ALRI were admitted to the ward for a median of 4 days (IQR, 3–7 days). Intensive care unit management was required in 51 patients (9%). The in-hospital mortality rate was 5% (28/570).
Although a viral infection was suspected, antibiotic therapy was initiated in more than half of the patients (325/570, 57%). Among them, 107 (33%) patients received two or more antibiotics during hospitalisation (Table 2), and the simultaneous use of two or more antibiotics was documented in 91 (28%) patients. Third-generation cephalosporins (55%) and amoxicillin/clavulanic acid (34%) were commonly prescribed, followed by amoxicillin/flucloucacinil (13%), cefoperazone/sulbactam (9%), ampicillin or penicillin G (7%), piperacillin/tazobactam (6%), azithromycin (4%), carbapenems (3%), and quinolones (2%).

**Laboratory and radiologic findings (Table 3, Table 4, and Supplementary Table 4)**

A complete blood count was obtained in 63% of the patients. The median white blood cell count was 13.4 × 10^3/μL (IQR: 9.3 × 10^3/μL). C-reactive protein was measured in 41% of the patients and had a median of 1.6 mg/dL (IQR: 0.3-4.6 mg/dL). A chest radiograph was obtained in 59% of the patients, and consolidation and over-inflation were observed in 44% and 43% of the patients, respectively. Rapid diagnostic tests for both RSV and influenza were performed in 99% of the patients, with 128 (23%) and 23 (4%) patients testing positive for RSV and influenza, respectively (Table 4).

**Identified viruses (Table 5)**

The causative viruses were detected in 88% of the patients. The number of detected and detected viruses is summarised in Table 5. RSV B (36%) and hRV (28%) were the most commonly detected viruses, followed by hMPV (13%), adenovirus (13%), enteroviruses (12%), RSV A (10%), and influenza A (9%) (Table 5 and Figure 2). Comparing the infants (less than 12 months) and the group aged 6-12 years, RSV was more likely to be detected in infants (198 [52%] vs 54 [29%], P < 0.001). In contrast, influenza was less likely to be detected in infants (26 [7%] vs 27 [14%], P = 0.004).

In total, 12% (68/570) of the patients had no virus detected on RT-PCR, while 18% (12/68) were positive for RSV on the rapid test but were negative on PCR. The median age of the undetected cases was 8 months (IQR: 4–15 months), which was not significantly different from the detected cases (P = 0.91).

The epidemiological curves of representative viruses, including RSV, hRV, and influenza viruses, are shown in Figure 1. RSV predominated in both 2017 and 2018, with a peak in September. The detection of influenza started in June 2017, and the detection rate was lower in 2018. hRV has been detected throughout the years, with peaks in August 2017 and September 2018.

**Clinical symptoms and signs of the ALRI patients detected with a single virus (Table 6)**

The clinical symptoms and signs of ALRI classified by each single detected virus are summarised in Table 6. Comparing the symptoms and signs of the patients infected with each virus and those infected with a single virus, patients infected with RSV were more likely to develop rhonchi (99 [79%] vs 95 [57%], P < 0.001), and those infected with hMPV were less likely to develop prolonged capillary refill time (0 [0%] vs 23 [90%], P = 0.042). Furthermore, those infected with adenovirus had higher rates of coarse crackles (7 [88%] vs 143 [51%], P = 0.040). Other significant findings included higher rates of fever in those infected with influenza (16 [64%] vs 107 [40%], P = 0.021) and higher rates of cyanosis in those infected with hBoV (3 [75%] vs 34 [12%], P = 0.007) than in those infected with viruses other than the virus listed.

**ALRI patients detected with two or more viruses (Tables 5 and 7)**

Two or more viruses were detected in 211 patients (37%) (Table 5 and Figure 2), with the most common combinations being RSV and hRV (31%), followed by hRV and adenovirus (9%), and hRV and hMPV (7%) (Table 7). Among the cases with two or more viruses detected, 2.3% of the patients were fatal. There were no dominant viruses or specific combinations of the viruses specifically identified in fatal cases (Table 7).

Next, we evaluated the clinical impact of the number of viruses detected on the clinical outcomes. The in-hospital mortality did not differ among those detected with one virus (7%), two viruses (1%) (P = 0.07), or 3-5 viruses (6%) (P = 0.59). Similarly, the median length of hospitalisation did not differ significantly among those detected with one virus (4.0 days [IQR: 3.0–7.0 days]), two viruses (4.0 days [IQR: 3.0–6.0 days], P = 0.98), or 3-5 viruses (4.5 days [IQR: 3.0–7.0 days], P = 0.57) (Supplementary Table 3).

Next, we analysed the mortality and median length of hospitalisation in the patients detected with RSV only and those detected with RSV and hMPV and hBoV, which are often detected simultaneously with RSV. The mortality of those infected with RSV with or without hMPV (4% vs 0%, P = 0.66) or hBoV (25% vs 0%, P = 0.22) did not differ significantly. Similarly, the median length of hospitalisation among the patients infected with RSV with or without hMPV (4.0 days [IQR: 3.0–5.0 days] vs 4.0 days [IQR: 3.0–6.0 days], P = 0.90) or hBoV (7.5 days [IQR: 3.0–14.2 days] vs 3.5 days [IQR: 3.0–5.8 days], P = 0.65) did not differ significantly.

**Severe ALRI patients**

In total, 107 (19%) severe cases were identified. The median age did not differ between the severe (8 months [IQR: 3–12 months]) and non-severe cases (8 months, [IQR: 4–16 months]) (P = 0.39). The rate of cases that did not receive any routine immunisation was higher in the severe (22%)
than in the non-severe cases (10%) (P = 0.01). A single virus was detected in 58 (54%) patients with severe cases, with RSV B (34%) and hRV (33%) being the most common. Among the severe cases, 20/107 (19%) died during hospitalisation, while there were only 8/463 (2%) mortalities in the non-severe cases (P < 0.001).

**Fatal ALRI patients**

In total, 28 patients (4.9%) died. The median age did not differ between the fatal (7 months, IQR: 3–21 months) and non-fatal cases (8 months, IQR: 4–15 months) (P = 0.88). Stunting (39% [11/28] vs 23% [127/542], P = 0.056) and lack of immunisation (32% [9/28] vs 12% [63/542], P = 0.050) were more frequently observed in the fatal cases than in non-fatal cases.

Significant differences were observed in all the vital signs on admission between the fatal and non-fatal cases. Compared to the non-fatal cases, the fatal cases had a higher heart rate (160 bpm [IQR: 140–168 bpm] vs 140 bpm [IQR: 120–152 bpm], P = 0.001), body temperature (38.7 °C [IQR: 37.8–39.0 °C] vs 37.7 °C [IQR: 37.0–38.3 °C], P < 0.001), respiratory rate (69 bpm [IQR: 62–78 bpm], vs 60 bpm [IQR: 48–64 bpm], P < 0.001), and lower SpO2 (92% [IQR: 80–98%]) vs 96% [IQR: 94–98%], P = 0.024).

On physical examination, the following were more frequently observed in the fatal cases than in the non-fatal cases: coarse crackles (93% vs 49%, P < 0.001), wheezing (61% vs 36%, P = 0.008), grunting (75% vs 20%, P < 0.001), cyanosis (71% vs 8%, P < 0.001), and prolonged capillary refill time ≥3 s (11 [39%] vs 39 [7%], P < 0.001).

In 25/28 (89%) fatal cases, at least one virus was detected: one virus (n = 20, 71%), two viruses (n = 2, 7%), and three viruses (n = 3, 11%). Influenza A (29%) and RSV B (21%) were the most commonly detected viruses.

**Pneumococcal colonisation**

In total, 45% (259/570) of the patients were PCR-positive for pneumococcus (Table 5). Among those who had received the 10-valent PCV, 49% (130/264) were positive, which did not significantly vary compared to those who had not received the vaccine (42%, 129/306) (P = 0.090).

When we compared the positive rates for pneumococcus between the severe (39%) vs non-severe cases (47%) and the fatal (32%) vs non-fatal cases (46%), no significant differences were observed between the groups (P = 0.15, respectively).

**Discussion**

The current study conducted the first comprehensive investigation of hospitalised children with viral ALRI in Myanmar. We found several important facts: (1) the majority of the patients were infants admitted to the hospital 3 days after disease onset; (2) RSV and hRV were the leading viral causes of ALRI, whereas influenza virus was the most frequently detected in the fatal cases, and (3) the mortality rate was high, close to 5%. These findings provide important information to better understand viral ALRI and design strategies for evaluating, managing, and reducing mortality in children with ALRI in Myanmar.

In the current study, the overall mortality rate was 4.9%, higher than the rates reported by previous studies conducted in both developing and developed countries among hospitalised children with ALRI. The case-fatality ratios due to severe ALRI in admitted children younger than 5 years were estimated to be 2.3% (1.6–3.4%) in developing countries and 0.6% (0.4–0.8%) in developed countries (40), with an exception in eastern Mediterranean countries (7.6%; 4.9%–7.9%) (40). The factors affecting mortality were also investigated, including underlying neurological diseases (41), high rates of severe stunting (21%) (41), or insufficient data (40, 42). In the current study, the rate of stunting was high (25%), though it did not differ significantly between fatal and non-fatal cases. Of note, stunting was the leading risk factor for ALRI mortality among children younger than 5 years, responsible for 61.4% of deaths due to ALRI (8, 12).

All vital signs were significantly different between the fatal and non-fatal cases. Additionally, abnormal respiratory sounds, grunting, cyanosis, and prolonged capillary refill time were more frequently observed in the fatal cases. As a screening tool for severe ALRI, none of the vital signs provided conclusive evidence. For example, fever was classified in the WHO guideline to have a low sensitivity and specificity (43). However, the attentive measurement of vital signs and physical examination might be helpful for clinicians to predict patients with high mortality. Furthermore, severe cases in the current study were more likely to turn into fatal cases, highlighting the importance of the early identification of severe cases.

Notably, 89% of the fatal cases were detected with at least one virus, with influenza A (29%) being the most commonly detected virus, followed by RSV (25%). Recent global investigations have demonstrated that RSV is the leading viral aetiology of ALRI mortality in children (5), while influenza is more frequently associated with non-fatal ALRI episodes than with fatal episodes (5). Contrary to this finding, our study demonstrated that influenza was the leading cause of death among the hospitalised children with ALRI in Myanmar.
In the current study, RSV was the most frequently detected virus, followed by hRV, hMPV, and adenovirus, consistent with the results of previous studies evaluating viral aetiologies in children with ALRI from neighbouring countries, such as Bangladesh, Thailand, and India (11, 12). In particular, RSV had the highest burden of ALRI in infants compared to other age groups, which was consistent with the findings of previous studies (9, 44). The peak of ALRI in the current study occurred from August to October, which coincides with the second half of the rainy season. In contrast, the influenza season occurs in July or August, the first half of the rainy season (23, 45).

The clinical manifestations of ALRI depend on the viral aetiology. Influenza was more likely to manifest with fever, rhinorrhoea, cyanosis, and wheezing. However, overlapping clinical presentations were frequently observed in the detected viruses, as in previous studies (13, 46). Compared to other viruses, it has also been reported that RSV-related ALRIs frequently presented with crackles, wheezing, chest indrawing, and rhinorrhoea (47-50), but these were not observed in the current study.

In the 107 severe cases that presented with signs of respiratory distress and required oxygen supplementation, RSV was the most frequently detected virus (43%), followed by hRV (33%), influenza (11%), and EV (11%). In most studies, RSV has been characterised to have a more severe presentation than other viruses (49, 51, 52), which is consistent with the current results. However, some studies concluded that severity was not associated with a certain virus (53-55).

Our study demonstrated that 37% of patients were infected with two or more viruses from one nasopharyngeal sample. The common combinations of the viruses were RSV and hRV, followed by RSV and adenovirus, and adenovirus and hRV. The local epidemiology of these combinations may differ depending on the location, climate, and season. For example, RSV and hBoV or influenza and hBoV were reported to be the most common combinations in children with ALRI in the United Kingdom (56, 57). The current study demonstrated no significant differences in the in-hospital mortality and length of hospitalisation between the patients detected with one virus and those with two or more viruses. This finding was consistent with a previous systematic review and meta-analysis, which concluded that there were no differences in the clinical severity and mortality of ALRI in children detected with single or multiple viruses (58, 59).

The most important clinical question is which combination of the viruses affects morbidity and mortality. RSV, hRV, and influenza, the common causes of childhood ALRI, are associated with high morbidity and mortality as single causative pathogens (5, 60-63). As such, coinfection with these viruses may cause higher morbidity and mortality than a single virus. Different pathological mechanisms could be triggered by different viruses, which facilitate or inhibit the effects of each virus by the direct interactions of viral genes or the indirect interactions resulting from alterations in the host environment or immunological interactions (64, 65). For example, the combination of RSV and hMPV infection has been proposed to increase disease severity compared to RSV infection alone (66, 67). Our study demonstrated that there were no significant differences in the in-hospital mortality and the length of hospitalisation between the patients with RSV infection alone and those infected with the combination of RSV and hMPV, which was similar to previous reports (68, 69). Of note, in contrast to these results, one study in Italy demonstrated that RSV-infected patients had a longer hospitalisation and higher hypoxia rates than the combination of RSV- and hMPV-infected patients (70). Further studies are warranted to understand the impact of coinfection with RSV and hMPV.

Similarly, several studies have focused on evaluating the impact of hBoV and its coinfection. hBoV was mainly discovered as a coinfection in Swedish children with ALRI of unknown aetiology in 2005 (71-75). One study reported that hBoV was responsible for severe ALRI presentation in children (76), but others reported no differences (77, 78). As for the coinfection of hBoV with other viruses, some studies have concluded that both hBoV- and RSV-infected patients had more severe presentations (79, 80) than hBoV-infected patients, while other studies indicated that the clinical presentation of the coinfection with hBoV- and RSV did not differ from hBoV infection alone (77), which was consistent with our results. Hence, the clinical significance of coinfection is still inconclusive, and further studies are needed.

Pneumococcal infection remains the leading cause of bacterial infection in children, despite the introduction of PCV (81, 82). In Myanmar, PCV was only recently introduced. As such, the rate of pneumococcal colonisation is unknown. To understand the role of pneumococcal colonisation in ALRI in children from Myanmar, we also evaluated the nasopharyngeal colonisation rates using PCR and found a high positive rate (up to 45%) in the nasopharynx. Previous studies evaluating the pneumococcal nasopharyngeal colonisation have shown similar rates, with 54.5% and 62.5% in children aged 2–59 months in India (83) and aged 1–59 months in Thailand (84), respectively. Our results demonstrated that pneumococcal colonisation was common in children from Myanmar, providing the baseline colonisation rate in the early stages of the 10-valent PCV's introduction. The importance of PCV in Myanmar has been confirmed, and the evaluation of pneumococcal serotypes in colonised individuals is warranted for future pneumococcal vaccine strategies in children in Myanmar, given that pneumococcal serotype replacement has become a major issue worldwide (85).

Our study revealed that RSV was the most frequently detected virus, and influenza was the leading cause of death among hospitalised children with ALRI in Myanmar. Medical professionals should reaffirm the significance of these two viruses. First, the introduction of palivizumab prophylaxis is needed to reduce both the RSV-related morbidity and mortality in children in Myanmar as this can prevent serious ALRI in high-risk infants and children (e.g. premature infants ≤35 weeks gestational age with chronic lung disease of prematurity and congenital heart disease) (86). Similarly, influenza vaccines can prevent hospitalisation due to influenza in children (87, 88). Thus, the strengthening of prevention programs will improve the health of children in Myanmar, though further studies are needed to clarify the effectiveness of these prevention interventions in
Written consent was obtained from all the study participants, including their parents and guardians, before they participated in the study. Consent for publication

This study was approved by the ethics committees of the Department of Medical Research, Ministry of Health and Sports, Myanmar (016616) and Niigata University, Japan (2547). Written consent was obtained from all the study participants, including their parents and guardians, before they participated in the study. Consent for publication

Written consent was obtained from all the study participants, including their parents and guardians, before they participated in the study.
Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the International Development Strategy Program for Infectious Diseases Research (J-GRID) of AMED (Japan Medical Research and Development Organization) (15fm0108009h0001- 19fm0108009h0005), Japan.

Author's contributions

KK conceived this study, contributed to the acquisition of data, interpreted the data, and drafted the manuscript. KNT, HHT, HW and RS conceived and designed this study, and contributed to the acquisition of data. LD and TO contributed to the acquisition of data. NCW performed the microbiological test. SMKW, YS, AI HO, IC and WWP performed the PCR test. YA, TI, YK, and YS conceived and designed this study. AS conceived and designed this study, contributed to the acquisition of data, interpreted the data, and drafted and edited the manuscript. All of the authors approved the final manuscript.

Acknowledgments

The authors acknowledge all the participants, parents, and health care workers who participated in the study. The authors would like to thank Drs Kyaw Zin Wai, Cho Win, Le Tun, Chaw Sandar Tun, Ni Htwe, Ye Kyaw Thu, and Junko Ishida for their assistance with data collection at YKCH. The authors are also grateful to Drs. Aye Tun, Aye Thida, San Mya, and Latt Kyaw for their constructive suggestions and continuous support to this research.

Abbreviations

ALRI: acute lower respiratory infection
hBoV: human bocavirus
hRV: human rhinovirus
PIV: parainfluenza virus
RSV: respiratory syncytial virus

References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88.
2. Wang X, Li Y, Deloria-Knoll M, Madhi SA, Cohen C, Ali A, et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. Lancet Glob Health. 2021;9(1):e33-e43.
3. Andersen P. Pathogenesis of lower respiratory tract infections due to Chlamydia, Mycoplasma, Legionella and viruses. Thorax. 1998;53(4):302-7.
4. Howie SRC, Murdoch DR. Global childhood pneumonia: the good news, the bad news, and the way ahead. Lancet Glob Health. 2019;7(1):e4-e5.
5. Collaborators GLRI. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191-210.
6. Sidhu S, Villar R. One child dies of pneumonia every 39 seconds, agencies warn. UNICEF. 2019. [https://www.unicef.org/press-releases/one-child-dies-pneumonia-every-39-seconds-agencies-warn](https://www.unicef.org/press-releases/one-child-dies-pneumonia-every-39-seconds-agencies-warn). Accessed 20 Apr 2021.

7. United Nations Inter-agency Group for Child Mortality Estimation. Levels & trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for Child Mortality Estimation. 2019. [https://childmortality.org/wp-content/uploads/2019/10/UN-IGME-Child-Mortality-Report-2019.pdf](https://childmortality.org/wp-content/uploads/2019/10/UN-IGME-Child-Mortality-Report-2019.pdf). Accessed 20 Apr 2021.

8. Sonego M, Pellegrin MC, Becker G, Lazzerini M. Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of age in low and middle-income countries: a systematic review and meta-analysis of observational studies. PLoS One. 2015;10(1):e0116380.

9. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835-45.

10. Nolan VG, Arnold SR, Bramley AM, Ampofo K, Williams DJ, Grijalva CG, et al. Etiology and impact of coinfections in children hospitalized with community-acquired pneumonia. J Infect Dis. 2018;218(2):179-88.

11. Rodrigues CMC, Groves H. Community-acquired pneumonia in children: the challenges of microbiological diagnosis. J Clin Microbiol. 2018;56(3).

12. The Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757-79.

13. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377(9773):1264-75.

14. Rhedin S, Lindstrand A, Hjelmgren A, Ryd-Rinder M, Ohrlalm L, Tolvenstam T, et al. Respiratory viruses associated with community-acquired pneumonia in children: matched case-control study. Thorax. 2015;70(9):847-53.

15. Self WH, Williams DJ, Zhu Y, Ampofo K, Pavia AT, Chappell JD, et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis. 2016;213(4):584-91.

16. Yeoh DK, Foley DA, Minney-Smith CA, Martin AC, Mace AQ, Sikazwe CT, et al. The impact of COVID-19 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis. 2020; doi: 10.1093/cid/ciaa1475.

17. World Health Organization Myanmar. Pneumococcal Vaccine (PCV) introduced in Myanmar, strengthening routine immunization activities. 2016. [http://origin.searo.who.int/myanmar/areas/immunization_PCV_vaccine/en/](http://origin.searo.who.int/myanmar/areas/immunization_PCV_vaccine/en/). WHO. Accessed 20 Apr 2021.

18. World Health Organization, Regional Office for South-East Asia. Expanded programme on Immunization (EPI) factsheet 2019: Myanmar. [https://apps.who.int/iris/handle/10665/329987](https://apps.who.int/iris/handle/10665/329987). Accessed 11 Jan 2021.

19. World Health Organization. WHO and UNICEF estimates of national immunization coverage: 2019 revision [https://www.who.int/immunization/monitoring_surveillance/data/mmr.pdf](https://www.who.int/immunization/monitoring_surveillance/data/mmr.pdf). Accessed 11 Jan 2021.

20. Hoehn T, Hoppenz M. Neonatal and childhood mortality rates in Myanmar. Klin Padiatr. 2009;221(4):266-8.

21. The state of the world’s children 2017. United Nations Children's Fund (UNICEF). 2017. [https://www.unicef.org/publications/les/SOWC_2017_ENG_WEB.pdf](https://www.unicef.org/publications/les/SOWC_2017_ENG_WEB.pdf). Accessed 20 Apr 2021.

22. Turner P, Turner C, Watthanaworawit W, Carrara V, Cicelia N, Deglise C, et al. Respiratory virus surveillance in hospitalised pneumonia patients on the Thailand-Myanmar border. BMC Infect Dis. 2013;13:434.

23. Htwe KTZ, Dapat C, Shobugawa Y, Odagiri T, Hibino A, Kondo H, et al. Phylogeographic analysis of human influenza A and B viruses in Myanmar, 2010-2015. PLoS One. 2019;14(1):e0210550.

24. United Nations Population Fund. United Nations Population Fund Myanmar. [https://myanmar.unfpa.org](https://myanmar.unfpa.org). Accessed 11 Jan 2021.

25. World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities: evidence summaries. 2014. [https://apps.who.int/iris/bitstream/handle/10665/137319/9789241507813_eng.pdf?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/137319/9789241507813_eng.pdf?sequence=1). Accessed 1 Jun 2021.

26. World Health Organization. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses. 2013. [https://www.who.int/maternal_child_adolescent/documents/child_hospital_care/en/](https://www.who.int/maternal_child_adolescent/documents/child_hospital_care/en/). Accessed 1 Jun 2021.
27. Hu A, Colella M, Tam JS, Rappaport R, Cheng SM. Simultaneous detection, subgrouping, and quantitation of respiratory syncytial virus A and B by real-time PCR. J Clin Microbiol. 2003;41(1):149-54.

28. Tozer SJ, Lambert SB, Whiley DM, Bialasiewicz S, Lyon MJ, Nissen MD, et al. Detection of human bocavirus in respiratory, fecal, and blood samples by real-time PCR. Journal of medical virology. 2009;81(3):488-93.

29. Dong H, Zhang Y, Xiong H, Yan A, Ding G, Chen Y, et al. Detection of human novel influenza A (H1N1) viruses using multi-fluorescent real-time RT-PCR. Virus Res. 2010;147(1):85-90.

30. Hindiyeh M, Levy V, Azar R, Varsano N, Regev L, Shalev Y, et al. Evaluation of a multiplex real-time reverse transcriptase PCR assay for detection and differentiation of influenza viruses A and B during the 2001-2002 influenza season in Israel. J Clin Microbiol. 2005;43(2):589-95.

31. Mohamed N, Elfaitouri A, Fohlman J, Friman G, Blomberg J. A sensitive and quantitative single-tube real-time reverse transcriptase-PCR for detection of enteroviral RNA. J Clin Virol. 2004;30(2):150-6.

32. Klemenc J, Asad Ali S, Johnson M, Tollefson SJ, Talbot HK, Hartert TV, et al. Real-time reverse transcriptase PCR assay for improved detection of human metapneumovirus. J Clin Virol. 2012;54(4):371-5.

33. Brittain-Long R, Nord S, Olofsson S, Westin J, Anderson LM, Lindh M. Multiplex real-time PCR for detection of respiratory tract infections. J Clin Virol. 2008;41(1):53-6.

34. van de Pol AC, van Loon AM, Wolfs TF, Jansen NJ, Nijhuis M, Breteler EK, et al. Increased detection of respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenoviruses with real-time PCR in samples from patients with respiratory symptoms. J Clin Microbiol. 2007;45(7):2260-2.

35. Morikawa S, Hiroi S, Kase T. Detection of respiratory viruses in gargle specimens of healthy children. J Clin Virol. 2015;64:59-63.

36. Wong S, Pabbaraju K, Pang XL, Lee BE, Fox JD. Detection of a broad range of human adenoviruses in respiratory tract samples using a sensitive multiplex real-time PCR assay. J Med Virol. 2008;80(5):856-65.

37. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol. 2006;44(1):124-31.

38. Centers for Disease Control and Prevention. Conventional PCR deduction of 40 Pneumococcal serotypes or serogroups https://www.cdc.gov/streplab/pneumococcus/resources.html. Accessed 16 Dec 2020.

39. Centers for Disease Control and Prevention. Conventional PCR serotype deduction protocols https://www.cdc.gov/streplab/pneumococcus/resources.html. Accessed 16 Dec 2020.

40. Nair H, Simões EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JSF, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet. 2013;381(9875):1380-90.

41. Mirkarimi M, Alisamir M, Saraf S, Heidari S, Barouti S, Mohammadi S. Clinical and epidemiological determinants of lower respiratory tract infections in hospitalized pediatric patients. Int J Pediatr. 2020;2020:8844420.

42. Rudan I, Lawn J, Cousens S, Rowe AK, Boschi-Pinto C, Tomasković L, et al. Gaps in policy-relevant information on burden of disease in children: a systematic review. Lancet. 2005;365(9476):2031-40.

43. World Health Organization. Technical bases for the WHO recommendations on the management of pneumonia in children at first-level health facilities. 1991.

44. García-García ML, Calvo C, Pozo F, Villadangos PA, Pérez-Breña P, Casas I. Spectrum of respiratory viruses in children with community-acquired pneumonia. Pediatr Infect Dis J. 2012;31(8):808-13.

45. Kyaw Win SM, Saito R, Win NC, Lasham DJ, Kyaw Y, Lin N, et al. Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017. PLoS One. 2020;15(3):e0229601.

46. Lanaspa M, Annamalay AA, LeSouëf P, Bassat Q. Epidemiology, etiology, x-ray features, importance of co-infections and clinical features of viral pneumonia in developing countries. Expert Rev Anti Infect Ther. 2014;12(1):31-47.

47. Lamarão LM, Ramos FL, Mello WA, Santos MC, Barbagelata LS, Justino MC, et al. Prevalence and clinical features of respiratory syncytial virus in children hospitalized for community-acquired pneumonia in northern Brazil. BMC Infect Dis. 2012;12:119.
48. Loscertales MP, Roca A, Ventura PJ, Abacassamo F, Dos Santos F, Sitaube M, et al. Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. Pediatr Infect Dis J. 2002;21(2):148-55.

49. Mathisen M, Strand TA, Sharma BN, Chandyo RK, Valentinent-Branth P, Basnet S, et al. Clinical presentation and severity of viral community-acquired pneumonia in young Nepalese children. Pediatr Infect Dis J. 2010;29(1):e1-6.

50. Nokes DJ, Ngama M, Bett A, Abwao J, Munywoki P, English M, et al. Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis. 2009;49(9):1341-9.

51. Kaplan NM, Dove W, Abd-Eldayem SA, Abu-Zeid AF, Shamoon HE, Hart CA. Molecular epidemiology and disease severity of respiratory syncytial virus in relation to other potential pathogens in children hospitalized with acute respiratory infection in Jordan. J Med Virol. 2008;80(1):168-74.

52. Miller EK, Khuri-Bulos N, Williams JV, Shehabi AA, Faouri S, Al Jundi I, et al. Human rhinovirus C associated with wheezing in hospitalised children in the Middle East. J Clin Virol. 2009;46(1):85-9.

53. Sentilhes AC, Choumlivong K, Celhoy O, Sisouk T, Phonekeo D, Vongphrachanh P, et al. Respiratory virus infections in hospitalized children and adults in Lao PDR. Influenza Other Respir Viruses. 2013;7(6):1070-8.

54. Johnson BR, Osinusui K, Aderle WI, Tomori O. Viral pathogens of acute lower respiratory infections in pre-school Nigerian children and clinical implications of multiple microbial identifications. West Afr J Med. 1993;12(1):11-20.

55. Guerrier G, Goyet S, Chheng ET, Rammaert B, Borand L, Te V, et al. Acute viral lower respiratory tract infections in Cambodian children: clinical and epidemiologic characteristics. Pediatr Infect Dis J. 2013;32(1):e8-13.

56. Duyu M, Karakaya Z. Viral etiology and outcome of severe lower respiratory tract infections among critically ill children admitted to the PICU. Med Intensiva. 2020; doi: 10.1016/j.medin.2020.04.023

57. Scotta MC, Chakr VC, de Moura A, Becker RG, de Souza AP, Jones MH, et al. Respiratory viral coinfection and disease severity in children: A systematic review and meta-analysis. J Clin Virol. 2016;80:45-56.

58. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev. 2006;19(3):571-82.

59. Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S, et al. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. Arch Pediatr Adolesc Med. 2012;166(8):700-6.

60. Yen CY, Wu WT, Chang CY, Wong YC, Lai CC, Chan YJ, et al. Viral etiologies of acute respiratory tract infections among hospitalized children - A comparison between single and multiple viral infections. J Microbiol Immunol Infect. 2019;52(6):902-10.

61. Lazar I, Weibel C, Dziura J, Ferguson D, Landry ML, Kahn JS. Human metapneumovirus and severity of respiratory syncytial virus disease. Emerg Infect Dis. 2004;10(7):1318-20.
69. Wolf DG, Greenberg D, Kalkstein D, Shemer-Avni Y, Givon-Lavi N, Saleh N, et al. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J. 2006;25(4):320-4.

70. Canducci F, Debiaggi M, Sampaolo M, Marinozzi MC, Berrè S, Terulla C, et al. Two-year prospective study of single infections and co-infections by respiratory syncytial virus and viruses identified recently in infants with acute respiratory disease. J Med Virol. 2008;80(4):716-23.

71. García-García ML, Calvo Rey C, Pozo Sánchez F, Vázquez Alvarez MC, González Vergaz A, Pérez-Breña P, et al. Human bocavirus infections in Spanish 0-14 year-old: clinical and epidemiological characteristics of an emerging respiratory virus. An Pediatr (Barc). 2007;67(3):212-9.

72. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA. 2005;102(36):12891-6.

73. Brieu N, Guyon G, Rodière M, Segondy M, Foulongne V. Human bocavirus infection in children with respiratory tract disease. Pediatr Infect Dis J. 2008;27(11):969-73.

74. Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R, et al. Human bocavirus and acute wheezing in children. Clin Infect Dis. 2007;44(7):904-10.

75. Schildgen O, Müller A, Allander T, Mackay IM, Völz S, Kupfer B, et al. Human bocavirus: passenger or pathogen in acute respiratory tract infections? Clin Microbiol Rev. 2008;21(2):391-304, table of contents.

76. Martin ET, Fairchok MP, Kuypers J, Magaret A, Zerr DM, Wald A, et al. Frequent and prolonged shedding of bocavirus in young children attending daycare. J Infect Dis. 2010;201(11):1625-32.

77. Petrarca L, Nenna R, Frassanito A, Pierangeli A, Di Mattia G, Scagnolari C, et al. Human bocavirus in children hospitalized for acute respiratory tract infection in Rome. World J Pediatr. 2020;16(3):293-8.

78. do Amaral de Leon C, Amantea SL, Pilger DA, Cantarelli V. Clinical and epidemiologic profile of lower respiratory tract infections associated with human bocavirus. Pediatr Pulmonol. 2013;48(11):342-51.

79. Sun H, Sun J, Ji W, Hao C, Yan Y, Chen Z, et al. Impact of RSV coinfection on human bocavirus in children with acute respiratory infections. J Trop Pediatr. 2019;65(4):342-51.

80. Calvo C, García-García ML, Pozo F, Paula G, Molinero M, Calderón A, et al. Respiratory syncytial virus coinfections with rhinovirus and human bocavirus in hospitalized children. Medicine (Baltimore). 2015;94(42):e1788.

81. Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev. 2012;25(3):409-19.

82. Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12:207.

83. Sutcliffe CG, Shet A, Varghese R, Veeraraghavan B, Manoharan A, Wahl B, et al. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study. BMC Infect Dis. 2019;19(1):605.

84. Piralam B, Prosperi C, Thamthitiwat S, Bunthi C, Sawatwong P, Sangwichian O, et al. Pneumococcal colonization prevalence and density among Thai children with severe pneumonia and community controls. PLoS One. 2020;15(4):e0232151.

85. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113.

86. Anderson EJ, Carosone-Link P, Yoge R, Yi J, Simões EAF. Effectiveness of palivizumab in high-risk infants and children: a propensity score weighted regression analysis. Pediatr Infect Dis J. 2017;36(8):699-704.

87. Chung JR, Flannery B, Gagliani M, Smith ME, Reis EC, Hickey RW, et al. Patterns of influenza vaccination and vaccine effectiveness among young US children who receive outpatient care for acute respiratory Tract Illness. JAMA Pediatr. 2020;174(7):705-13.

88. Boddington NL, Warburton F, Zhao H, Andrews N, Ellis J, Donati M, et al. Influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children in England in the 2015-2016 influenza season - a test-negative case-control study. Epidemiol Infect. 2019;147:e201.
89. Akaishi Y, Matsumoto T, Harada Y, Hirayama Y. Evaluation of the rapid influenza detection tests GOLD SIGN FLU and Quick Navi-Flu for the detection of influenza A and B virus antigens in adults during the influenza season. Int J Infect Dis. 2016;52:55-8.

90. Kohiyama R, Miyazawa T, Shibano N, Inano K. Differentiation of influenza (Flu) type A, type B, and respiratory syncytial virus (RSV) by QuickNavi™-Flu+RSV. Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi. 2014;24(2):51-6.

91. Swe MMM, Hlaing PH, Phyoe AP, Aung HH, Smithuis F, Ashley EA, et al. Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. PLoS One. 2020;15(7):e0235625.

92. Reed C, Kallen AJ, Patton M, Arnold KE, Farley MM, Hageman J, et al. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. Pediatr Infect Dis J. 2009;28(7):572-6.

93. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005;353(24):2559-67.

94. MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis. 2018;18(1):637.

95. Finelli L, Fiore A, Dhara R, Brammer L, Shay DK, Kamimoto L, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122(4):805-11.

96. Nozaki I, Hachiya M, Kitamura T. Factors influencing basic vaccination coverage in Myanmar: secondary analysis of 2015 Myanmar demographic and health survey data. BMC Public Health. 2019;19(1):242.

97. Aung T, Tun KM, Thinn K, Thein AA. Knowledge, attitudes and practices of mothers on childhood acute respiratory infections (ARI). Southeast Asian J Trop Med Public Health. 1994;25(3):590-3.

98. Scott JA, Wonodi C, Moiisi JC, Deloria-Knoll M, DeLuca AN, Karron RA, et al. The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clin Infect Dis. 2012;54 Suppl 2:S109-16.

Tables

Table 1. Clinical characteristics of patients with ALRI according to age and severity (n = 570)
| Characteristics | Total N (%) | Age category (%) | Case category (%) |
|-----------------|-------------|------------------|-------------------|
|                 |             | 1-11 months old  | 1-5 years old     | 6-12 years old  | Non-severe cases | Severe cases | Fatal cases |
| Total N (%)     | 570         | 381 (67)         | 178 (31)          | 11 (2)          | 463 (81)        | 107 (19)     | 28 (5)      |
| **Median Age**  |             |                  |                   |                |                |              |             |
| [months] [IQR]  |             | 8.0 [4.0-15.0]   | 20.0 [15.0-31.0]  | 84.0 [78.5-102.0] | 8.0 [4.0-16.0] | 8.0 [3.0-12.0] | 7.0 [3.0-21.0] |
| **Male**        |             | 322 (56)         | 221 (58)          | 94 (53)        | 7 (64)         | 274 (59)     | 48 (45)     | 11 (39) |
| **Weight-for-age Z score** |       |                   |                   |                |                |              |             |
| Severe (< -3)   |             | 66 (12)          | 40 (10)           | 24 (13)        | 2 (18)         | 53 (11)      | 13 (12)     | 7 (25)  |
| Moderate (≥ -3 to < -2) | | 72 (13)          | 38 (10)           | 32 (18)        | 2 (18)         | 59 (13)      | 13 (12)     | 4 (14)  |
| Normal (≥ -2)   |             | 432 (76)         | 303 (80)          | 122 (69)       | 7 (64)         | 351 (76)     | 81 (76)     | 17 (61) |
| **Underling Diseases** | | 73 (13)         | 43 (11)           | 29 (16)        | 1 (9)          | 48 (10)      | 25 (23)     | 10 (36) |
| **Smoker in Family** |       | 243 (43)         | 163 (43)          | 75 (42)        | 5 (45)         | 183 (40)     | 60 (56)     | 15 (54) |
| **Immunization** |             |                   |                   |                |                |              |             |
| DPT             |             | 422 (74)         | 259 (68)          | 154 (87)       | 9 (82)         | 354 (76)     | 68 (64)     | 14 (50) |
| Hib             |             | 374 (66)         | 235 (62)          | 132 (74)       | 7 (64)         | 314 (68)     | 60 (56)     | 11 (39) |
| BCG             |             | 460 (81)         | 295 (77)          | 157 (88)       | 8 (73)         | 387 (84)     | 73 (68)     | 14 (50) |
| MR              |             | 138 (24)         | 33 (9)            | 99 (56)        | 6 (55)         | 115 (25)     | 23 (22)     | 6 (21)  |
| PCV             |             | 264 (46)         | 165 (43)          | 95 (53)        | 4 (36)         | 223 (48)     | 41 (38)     | 9 (32)  |
| None            |             | 72 (13)          | 61 (16)           | 11 (6)         | 1 (9)          | 48 (10)      | 24 (22)     | 9 (32)  |
| **History**     |             |                   |                   |                |                |              |             |
| Sick contact    |             | 65 (11)          | 44 (12)           | 20 (11)        | 1 (9)          | 51 (11)      | 14 (13)     | 5 (18)  |
| Symptoms Onset  |             | 3.0 [1.5-4.0]    | 3.0 [2.0-4.0]     | 2.0 [1.0-4.0]  | 3.0 [2.3-4.8]  | 2.0 [1.0-4.0] | 3.0 [2.0-6.0] |       |
| **Symptoms**    |             |                   |                   |                |                |              |             |
| Cough           |             | 534 (94)         | 357 (94)          | 168 (94)       | 9 (82)         | 432 (93)     | 102 (95)    | 26 (93) |
| Difficult Breathing |       | 415 (73)         | 287 (75)          | 121 (68)       | 7 (64)         | 324 (70)     | 91 (85)     | 28 (100) |
| Rhinorrhea      |             | 247 (43)         | 161 (42)          | 82 (46)        | 4 (36)         | 205 (44)     | 42 (39)     | 16 (57) |

All categorical data are presented as numbers (percentage, %). Continuous data are presented as median (interquartile range).

Abbreviations: ALRI: acute lower respiratory infection; Total N: total number; IQR: interquartile range; DPT: a combination vaccine of diphtheria, pertussis, and tetanus; Hib: *Haemophilus influenzae* type b vaccine; BCG: Bacille Calmette-Guérin vaccine; MR: Measles vaccine; PCV: pneumococcal conjugate vaccines.

Table 2. Clinical signs, course, and outcomes of children with ALRI according to age and severity (n = 570)
| Total N (%) | Age category (%) | Case category (%) |
|------------|------------------|-------------------|
|            | 1-11 months old | 1-5 years old | 6-12 years old | Non-severe cases | Severe cases | Fatal cases |
| Total N (%) | 570 | 381 (67) | 178 (31) | 11 (2) | 463 (81) | 107 (19) | 28 (5) |

### Vital Signs

| | | | | | | |
|---|---|---|---|---|---|---|
| Tachycardia | 208 (36) | 85 (22) | 116 (65) | 7 (64) | 147 (32) | 61 (57) | 18 (64) |
| Heart Rate [m] [IQR] | 140 [122-152] | 140 [128-156] | 132 [120-150] | 120 [120-150] | 135 [120-148] | 160 [140-164] | 160 [140-168] |
| Tachypnoea | 443 (78) | 280 (73) | 155 (87) | 8 (73) | 344 (74) | 99 (93) | 27 (96) |
| Respiratory Rate [m] [IQR] | 60 [48-64] | 60 [52-64] | 56 [44-64] | 49 [42-55] | 56 [48-62] | 64 [60-70] | 69 [62-78] |

### Clinical Signs

| | | | | | | |
|---|---|---|---|---|---|---|
| Chest indrawing | 383 (67) | 260 (68) | 116 (65) | 7 (64) | 290 (63) | 93 (87) | 24 (86) |
| Coarse crackles | 291 (51) | 191 (50) | 95 (53) | 5 (45) | 206 (44) | 85 (79) | 26 (93) |
| Wheezing | 212 (37) | 145 (38) | 63 (35) | 4 (36) | 160 (35) | 52 (49) | 17 (61) |
| Rhonchi | 357 (63) | 256 (67) | 99 (56) | 2 (18) | 291 (63) | 66 (62) | 15 (54) |
| Asymmetry of lung sounds | 18 (3) | 8 (2) | 8 (4) | 2 (18) | 6 (1) | 12 (11) | 5 (18) |
| Normal lung sounds | 29 (5) | 11 (3) | 17 (10) | 1 (9) | 26 (6) | 3 (3) | 1 (4) |
| Grunting | 130 (23) | 99 (26) | 30 (17) | 1 (9) | 63 (14) | 67 (63) | 21 (75) |
| Cyanosis | 65 (11) | 44 (12) | 21 (12) | 0 (0) | 0 (0) | 65 (61) | 20 (71) |
| Capillary refill time ≥ 3 sec | 50 (9) | 30 (8) | 19 (11) | 1 (9) | 25 (5) | 25 (23) | 11 (39) |

### Treatment

| | | | | | | |
|---|---|---|---|---|---|---|
| Antibiotics | 325 (57) | 204 (54) | 114 (64) | 7 (64) | 236 (51) | 89 (83) | 28 (100) |
| 2 or more than 2 drugs | 107 (19) | 71 (19) | 33 (19) | 3 (27) | 64 (14) | 43 (40) | 17 (61) |
| Anti-viral Treatment | 12 (2) | 4 (1) | 7 (4) | 1 (9) | 11 (2) | 1 (1) | 0 (0) |
| ICU Management | 51 (9) | 32 (8) | 18 (10) | 1 (9) | 12 (3) | 39 (36) | 14 (50) |
| O₂ Supply | 328 (58) | 232 (61) | 89 (50) | 7 (64) | 231 (50) | 97 (91) | 27 (96) |
| Mechanical Ventilation | 39 (7) | 25 (7) | 13 (7) | 1 (9) | 7 (2) | 32 (30) | 12 (43) |
| CPAP | 14 (2) | 14 (4) | 0 (0) | 0 (0) | 8 (2) | 6 (6) | 3 (11) |
| Fluid infusion | 176 (31) | 122 (32) | 48 (27) | 6 (55) | 115 (25) | 61 (57) | 24 (86) |

### Outcomes

| | | | | | | |
|---|---|---|---|---|---|---|
| In-hospital mortality | 28 (5) | 18 (5) | 10 (6) | 0 (0) | 8 (2) | 20 (19) | 28 (100) |
| Sequelae | 8 (1) | 5 (1) | 3 (2) | 0 (0) | 5 (1) | 3 (3) | |
| Length of hospitalization [day] [IQR] | 4.0 [3.0-7.0] | 4.0 [3.0-6.0] | 4.0 [3.0-7.0] | 7.0 [4.0-8.5] | 4.0 [3.0-6.0] | 7.0 [4.0-10.0] | 5.5 [1.0-12.0] |

All categorical data are presented as numbers (percentage, %). Continuous data are presented as median (interquartile range).

Abbreviations: ALRI: acute lower respiratory infection; Total N: total number; IQR: interquartile range; ICU: intensive care unit; CPAP: continuous positive airway pressure.
Table 3. Laboratory and radiologic findings in patients ALRI according to age and severity (N = 570)

|                          | Total N (%) | Age category (%) | Case category (%) |
|--------------------------|-------------|------------------|-------------------|
|                          |             | 1-11 months old  | 1-5 years old     | 6-12 years old | Non-severe cases | Severe cases | Fatal cases |
|                          |             | 1-5 years old    | 6-12 years old    |              |                 |              |             |
|                          | 570         | 381 (67)         | 178 (31)          | 11 (2)        | 463 (81)        | 107 (19)     | 28 (5)      |
| Total N (%)              |             |                  |                   |              |                 |              |             |
| CBC                      | 361 (63)    | 224 (59)         | 128 (72)          | 9 (82)        | 272 (59)        | 89 (83)      | 27 (96)     |
| Numbers of tests         |             |                  |                   |              |                 |              |             |
| performed (%)            |             |                  |                   |              |                 |              |             |
| WBC [x10^3/µL] [IQR]     | 13.4 [9.7-18.6] | 13.6 [10.0-18.1] | 12.6 [9.0-18.4]  | 22.0 [10.5-26.1] | 12.7 [9.3-17.3] | 15.9 [12.0-21.0] | 20.0 [12.9-24.9] |
| Neutrophil [%]           | 50 [37-69]  | 50 [36-69]       | 50 [37-69]       | 50 [37-69]    | 50 [37-69]      | 50 [36-69]   | 51 [38-69]  |
| Hemoglobin [g/dL] [IQR]  | 10.4 [9.6-11.2] | 10.3 [9.5-11.1]  | 10.8 [9.8-11.5]  | 10.4 [9.5-11.0] | 10.4 [9.7-11.2] | 10.3 [9.4-11.2] | 10.4 [9.2-11.5] |
| Platelets [x10^3/µL] [IQR] | 393 [285-507] | 412 [308-533]   | 366 [255-452]    | 332 [277-479] | 394 [293-500]  | 389 [249-521] | 277 [182-480] |
| Chemistry                | 231 (41)    | 133 (35)         | 90 (51)           | 8 (73)        | 171 (37)        | 60 (56)      | 19 (68)     |
| Numbers of tests         |             |                  |                   |              |                 |              |             |
| performed (%)            |             |                  |                   |              |                 |              |             |
| C-reactive protein       | 1.6 [0.3-4.6] | 1.3 [0.2-3.8]  | 1.9 [0.5-4.7]    | 9.5 [0.6-11.9] | 1.5 [0.2-4.2]  | 1.7 [0.5-5.5] | 1.8 [0.8-5.2] |
| [mg/dL][IQR]             |             |                  |                   |              |                 |              |             |
| Chest X-ray              | 336 (59)    | 209 (55)         | 118 (66)          | 9 (82)        | 250 (54)        | 86 (80)      | 25 (89)     |
| Numbers of tests         |             |                  |                   |              |                 |              |             |
| performed (%)            |             |                  |                   |              |                 |              |             |
| Consolidation            | 148 (44)    | 86 (41)          | 57 (48)          | 5 (56)        | 88 (35)         | 60 (70)      | 20 (80)     |
| Overinflation            | 144 (43)    | 92 (44)          | 50 (42)          | 2 (22)        | 117 (47)        | 27 (31)      | 3 (12)      |
| Normal Finding           | 36 (11)     | 26 (12)          | 9 (8 )           | 1 (11)        | 34 (14)         | 2 (2 )       | 0 (0 )      |

Categorical data are presented as number (percentage, %). Continuous data are presented as median (interquartile range).

Abbreviations: ALRI: acute lower respiratory infection; Total N: total number; IQR: interquartile range; CBC: complete blood count; WBC: white blood cells; RSV: respiratory syncytial virus; PCR: polymerase chain reaction.

Table 4. Sensitivity and specificity of the rapid diagnostic tests for RSV and influenza virus

|                          | PCR          | Sensitivity (%) | Specificity (%) |
|--------------------------|--------------|----------------|-----------------|
|                          | Positive     | Negative       | Total           |
| Rapid Test Kits          | for RSV      |                |                 |
| Positive                 | 109          | 19             | 128             |
| Negative                 | 142          | 295            | 437             |
| Total                    | 251          | 314            | 565             |
| Rapid Test Kits          | for influenza virus |            |                 |
| Positive                 | 23           | 0              | 23              |
| Negative                 | 29           | 513            | 542             |
| Total                    | 52           | 513            | 565             |

Rapid diagnostic tests for RSV and influenza were performed in 99% of the enrolled patients, and their sensitivity and specificity were 43% and 94%, and 44% and 100%, respectively.

Abbreviations: RSV: respiratory syncytial virus; PCR: polymerase chain reaction.
Table 5. Viral aetiologies and rates of pneumococcal colonisation according to age and severity/mortality (n = 570)

| Detected Number(s) of Virus(es) | Total N (%) | Age category (%) | Case category (%) |
|---------------------------------|-------------|------------------|-------------------|
|                                 |             | 1-11 months old | 1-5 years old | 6-12 years old | Non-severe cases | Severe cases | Fatal cases |
| No virus                        | 68 (12)     | 48 (13)         | 18 (10) | 2 (18)  | 57 (12) | 11 (10) | 3 (11) |
| 1 virus                         | 291 (51)    | 196 (51)        | 88 (49)   | 7 (64)  | 233 (50) | 58 (54) | 20 (71) |
| 2 viruses                       | 163 (29)    | 106 (28)        | 56 (31)   | 1 (9)   | 131 (28) | 32 (30) | 2 (7)   |
| 3 viruses                       | 43 (8)      | 27 (7)          | 15 (8)    | 1 (9)   | 38 (8)  | 5 (5)   | 3 (11)  |
| 4-5 viruses                     | 5 (1)       | 4 (1)           | 1 (1)     | 0 (0)   | 4 (1)   | 1 (1)   | 0 (0)   |
| RSV (Any)                       | 252 (44)    | 198 (52)        | 54 (30)   | 0 (0)   | 206 (44) | 46 (43) | 7 (25)  |
| RSV A                           | 59 (10)     | 48 (13)         | 11 (6)    | 0 (0)   | 46 (10) | 13 (12) | 3 (11)  |
| RSV B                           | 203 (36)    | 158 (41)        | 45 (25)   | 0 (0)   | 167 (36) | 36 (34) | 6 (21)  |
| Influenza virus (Any)           | 53 (9)      | 26 (7)          | 24 (13)   | 3 (27)  | 41 (9)  | 12 (11) | 8 (29)  |
| Influenza virus A               | 51 (9)      | 25 (7)          | 23 (13)   | 3 (27)  | 39 (8)  | 12 (11) | 8 (29)  |
| Influenza virus B               | 2 (0)       | 1 (0)           | 1 (1)     | 0 (0)   | 2 (0)   | 0 (0)   | 0 (0)   |
| hMPV                            | 75 (13)     | 40 (10)         | 34 (19)   | 1 (9)   | 64 (14) | 11 (10) | 3 (11)  |
| Enterovirus                     | 69 (12)     | 36 (9)          | 32 (18)   | 1 (9)   | 57 (12) | 12 (11) | 4 (14)  |
| hRV                             | 161 (28)    | 123 (32)        | 35 (20)   | 3 (27)  | 126 (27) | 35 (33) | 4 (14)  |
| PIV (Any)                       | 32 (6)      | 18 (5)          | 14 (8)    | 0 (0)   | 29 (6)  | 3 (3)   | 1 (4)   |
| PIV1                            | 13 (2)      | 8 (2)           | 5 (3)     | 0 (0)   | 11 (2)  | 2 (2)   | 1 (4)   |
| PIV2                            | 11 (2)      | 5 (1)           | 6 (3)     | 0 (0)   | 11 (2)  | 0 (0)   | 0 (0)   |
| PIV3                            | 11 (2)      | 7 (2)           | 4 (2)     | 0 (0)   | 10 (2)  | 1 (1)   | 1 (4)   |
| hCoV NL63                       | 3 (1)       | 1 (0)           | 2 (1)     | 0 (0)   | 3 (1)   | 0 (0)   | 0 (0)   |
| hCoV OC43                       | 1 (0)       | 1 (0)           | 0 (0)     | 0 (0)   | 1 (0)   | 0 (0)   | 0 (0)   |
| hCoV 229E                       | 3 (1)       | 2 (1)           | 0 (0)     | 1 (9)   | 2 (0)   | 1 (1)   | 0 (0)   |
| hCoV HKU                        | 0 (0)       | 0 (0)           | 0 (0)     | 0 (0)   | 0 (0)   | 0 (0)   | 0 (0)   |
| Adenovirus                      | 76 (13)     | 34 (9)          | 39 (22)   | 3 (27)  | 65 (14) | 11 (10) | 2 (7)   |
| hBoV                            | 29 (5)      | 17 (4)          | 12 (7)    | 0 (0)   | 21 (5)  | 8 (7)   | 1 (4)   |
| Pneumococcal Colonization       | 259 (45)    | 170 (45)        | 83 (47)   | 6 (55)  | 217 (47) | 42 (39) | 9 (32)  |

*If two or more viruses were detected in one patient, each detected virus was counted and listed in the table.

All categorical data are presented as number (percentage, %).
Table 6. Symptoms and signs of patients with ALRI due to a single virus

| Detected viruses | Total N (%) | RSVa | Influenza virusb | hMPVc | Enterovirus | hRVd | PIV | hCoV | Adenovirusd | hBoV |
|------------------|-------------|------|-----------------|-------|-------------|------|-----|------|-------------|------|
| **Symptoms**     |             |      |                 |       |             |      |     |      |             |      |
| Cough            | 271 (93)    | 119  | 25 (100)        | 32 (89) | 31 (94)    | 51 (91) | 3 (100) | 1 (100) | 5 (63) | 4 (100) |
| Difficult Breathing | 215 (74) | 92 (74) | 16 (64) | 25 (69) | 26 (79) | 44 (79) | 2 (67) | 1 (100) | 5 (63) | 4 (100) |
| Rhinorrhea       | 122 (42)    | 60 (48) | 15 (60) | 13 (36) | 17 (52) | 13 (23) | 1 (33) | 0 (0) | 1 (13) | 2 (50) |
| **Vital Signs**  |             |      |                 |       |             |      |     |      |             |      |
| Tachycardia      | 106 (36)    | 36 (29) | 8 (32) | 19 (53) | 14 (42) | 19 (34) | 2 (67) | 1 (100) | 4 (50) | 3 (75) |
| Tachypnoea       | 223 (77)    | 94 (75) | 17 (68) | 27 (75) | 29 (88) | 41 (73) | 3 (100) | 1 (100) | 7 (88) | 4 (100) |
| Fever ≥ 38°C     | 123 (42)    | 46 (37) | 16 (64) | 17 (47) | 17 (52) | 20 (36) | 1 (33) | 0 (0) | 4 (50) | 2 (50) |
| Hypoxaemia ≥ 90% | 41 (14)     | 17 (14) | 5 (20) | 3 (8) | 5 (15) | 6 (11) | 0 (0) | 1 (100) | 3 (38) | 1 (25) |
| **Clinical Signs** |          |      |                 |       |             |      |     |      |             |      |
| Chest indrawing  | 196 (67)    | 88 (70) | 15 (60) | 24 (67) | 24 (73) | 37 (66) | 1 (33) | 0 (0) | 4 (50) | 3 (75) |
| Coarse crackles  | 150 (52)    | 61 (49) | 11 (44) | 24 (67) | 16 (48) | 26 (46) | 2 (67) | 0 (0) | 7 (88) | 3 (75) |
| Wheezing         | 104 (36)    | 50 (40) | 12 (48) | 9 (25) | 15 (45) | 16 (29) | 0 (0) | 0 (0) | 1 (13) | 1 (25) |
| Rhonchi          | 194 (67)    | 99 (79) | 14 (56) | 16 (44) | 18 (55) | 39 (70) | 2 (67) | 0 (0) | 2 (25) | 4 (100) |
| Asymmetry of lung sounds | 8 (3) | 0 (0) | 3 (12) | 1 (3) | 3 (9) | 0 (0) | 0 (0) | 0 (0) | 1 (13) | 0 (0) |
| Normal lung sounds | 17 (6) | 1 (1) | 6 (24) | 2 (6) | 3 (9) | 4 (7) | 0 (0) | 1 (100) | 0 (0) | 0 (0) |
| Grunting         | 66 (23)     | 30 (24) | 6 (24) | 7 (19) | 5 (15) | 16 (29) | 0 (0) | 0 (0) | 1 (13) | 1 (25) |
| Cyanosis         | 37 (13)     | 10 (8) | 6 (24) | 3 (8) | 6 (18) | 8 (14) | 0 (0) | 0 (0) | 1 (13) | 3 (75) |
| Capillary refill time ≥ 3 sec | 23 (8) | 9 (7) | 3 (12) | 0 (0) | 3 (9) | 6 (11) | 0 (0) | 0 (0) | 1 (13) | 1 (25) |

Only single virus infected patients were counted and listed in the table.

1. RSV-infected patients were less likely to develop tachycardia (36 [29%] vs 70 [42%], P = 0.019) and cyanosis (10 [8%] vs 27 [16%], P = 0.036) but were more likely to develop rhonchi (99 [79%] vs 95 [57%], P < 0.001), compared to those infected with RSV alone.

2. The influenza virus-infected patients had higher rates of fever (16 [64%] vs 107 [40%], P = 0.021), compared to those infected with a virus other than influenza.

3. The hMPV-infected patients had higher rates of tachycardia (19 [53%] vs 87 [34%], P = 0.029), lower rates of rhonchi (16 [44%] vs 178 [70%], P = 0.003), and prolonged capillary refill time (0 [0%] vs 23 [90%], P = 0.042), compared to those infected with hMPV.

4. The hRV-infected patients had lower rates of rhinorrhea (13 [23%] vs 109 [46%], P = 0.002), compared to those infected with a virus other than hRV.
5. The adenovirus-infected patients had lower rates of cough (5 [63%] vs 266 [94%], P = 0.013) and rhonchi (2 [25%] vs 192 [68%], P = 0.018) and higher rates of coarse crackles (7 [88%] vs 143 [51%], P = 0.040), compared to those infected with adenovirus.

6. The hBoV-infected patients had higher rates of cyanosis (3 [75%] vs 34 [12%], P = 0.007) than those infected with hBoV.

All categorical data are presented as number (percentage, %).

Abbreviations: ALRI: acute lower respiratory infection; Total N: total number; RSV: respiratory syncytial virus; hMPV: human metapneumovirus; hRV: human rhinovirus; PIV: parainfluenza virus; hCoV: human coronaviruses; hBoV: human bocavirus; PCR: polymerase chain reaction.

Table 7. Viral combinations in patients with acute lower respiratory infection and in-hospital mortality

| Combination          | Number | Length of hospitalization [day][IQR] | In-hospital mortality |
|----------------------|--------|-------------------------------------|-----------------------|
| RSV + hRV            | 51     | 4.0 [3.0-5.8]                       | 0 ( 0 )               |
| hRV + Adenovirus     | 14     | 4.0 [3.0-6.0]                       | 0 ( 0 )               |
| hMPV + hRV           | 12     | 3.5 [2.0-5.0]                       | 1 ( 8 )               |
| Enterovirus + Adenovirus | 10   | 4.0 [3.0-4.0]                       | 0 ( 0 )               |
| Influenza + Adenovirus | 9    | 5.0 [3.0-10.0]                      | 1 (11)                |
| RSV + Enterovirus    | 8      | 6.0 [3.8-8.3]                       | 0 ( 0 )               |
| RSV + PIV            | 8      | 4.5 [3.0-5.3]                       | 0 ( 0 )               |
| RSV + Adenovirus     | 8      | 5.0 [3.8-6.3]                       | 0 ( 0 )               |
| hMPV + Adenovirus    | 6      | 3.5 [3.0-4.8]                       | 0 ( 0 )               |
| RSV + Influenza      | 5      | 3.0 [3.0-3.8]                       | 0 ( 0 )               |
| hRV + hBoV           | 5      | 5.0 [3.0-5.0]                       | 0 ( 0 )               |
| RSV + hMPV           | 4      | 4.5 [2.8-8.0]                       | 0 ( 0 )               |
| RSV + hBoV           | 4      | 7.5 [5.3-11.3]                      | 0 ( 0 )               |
| Influenza + Enterovirus | 2    | 4.0 [3.5-4.5]                       | 0 ( 0 )               |
| hMPV + Enterovirus   | 2      | 4.0 [4.0-4.0]                       | 0 ( 0 )               |
| Enterovirus + PIV    | 2      | 3.5 [2.8-4.3]                       | 0 ( 0 )               |
| Adenovirus + hBoV    | 2      | 4.0 [4.0-4.0]                       | 0 ( 0 )               |
| RSV + hCoV           | 1      | 1.0                                 | 0 ( 0 )               |
| Influenza + hMPV     | 1      | 7.0                                 | 0 ( 0 )               |
| Influenza + hRV      | 1      | 7.0                                 | 0 ( 0 )               |
| hMPV + PIV           | 1      | 3.0                                 | 0 ( 0 )               |
| Enterovirus + hBoV   | 1      | 14.0                                | 0 ( 0 )               |
| hRV + PIV            | 1      | 4.0                                 | 0 ( 0 )               |
| PIV + Adenovirus     | 1      | 16.0                                | 0 ( 0 )               |
| PIV + hBoV           | 1      | 14.0                                | 0 ( 0 )               |
| hCoV + hBoV          | 1      | 22.0                                | 0 ( 0 )               |

Only two kinds of virus-infected patients were counted and listed in the table.
Unlisted combinations, including influenza + PIV, influenza + hCoV, influenza + hBoV, hMPV + hCoV, hMPV + hBoV, enterovirus + hRV, enterovirus + hCoV, hRV + hCoV, PIV + hCoV, and adenovirus + hCoV, were not found in this study.

All categorical data are presented as numbers (percentage, %). Continuous data are presented as median (interquartile range).

Abbreviations: Total N: total number; RSV: respiratory syncytial virus; hMPV: human metapneumovirus; hRV: human rhinovirus; PIV: parainfluenza virus; hCoV: human coronaviruses; hBoV: human bocavirus.

Figures

Figure 1

Numbers of the detected viruses in admitted patients with acute lower respiratory infection. The total number of patients hospitalised under the diagnosis of acute lower respiratory infection in each month during the study period is shown (black line). Commonly detected viruses, including respiratory syncytial virus (light green bars), human rhinovirus (light blue bars), and influenza virus (blue bars) are independently shown. *If two or more viruses were detected in one patient, each detected virus was counted and accumulated in the bars. Abbreviations: RSV: respiratory syncytial virus; hRV: human rhinovirus; ALRI: acute lower respiratory infection.
Figure 2

Number of viruses detected by PCR in patients with acute lower respiratory infection. The number of cases in which a specific virus was detected is shown. A single virus (green bars) and multiple viruses (light green bars) are independently shown. The numbers in parentheses refer to coinfection rates. Abbreviations: RSV: respiratory syncytial virus; hMPV: human metapneumovirus; hRV: human rhinovirus; PIV: parainfluenza virus; hCoV: human coronaviruses; hBoV: human bocavirus.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supple20210608.docx